Dietary selenium and major depression: A nested case-control study by Pasco, Julie A. et al.
c
t
r
G
Z
a
SComplementary Therapies in Medicine (2012) 20,  119—123
Available  online  at  www.sciencedirect.com
jou rna l h om epa ge: www.elsev ierhea l th .com/ journa ls /c t im
Dietary  selenium  and  major  depression:  a  nested
case-control  study
Julie  A.  Pascoa,b,∗, Felice  N.  Jackaa,c, Lana  J.  Williamsa,c,
Melinda  Evans-Cleverdond,  Sharon  L.  Brennana,b,  Mark  A.  Kotowicza,b,
Geoffrey  C.  Nicholsone, Madeleine  J.  Ball d, Michael  Berka,c,f,g
a School  of  Medicine,  Deakin  University,  Geelong,  Victoria  3220,  Australia
b NorthWest  Academic  Centre,  Department  of  Medicine,  The  University  of  Melbourne,  St  Albans,  Victoria  3021,  Australia
c Department  of  Psychiatry,  The  University  of  Melbourne,  Parkville,  Victoria  3010,  Australia
d School  of  Human  Life  Sciences,  University  of  Tasmania,  Launceston,  Tasmania  7250,  Australia
e Rural  Clinical  School,  School  of  Medicine,  The  University  of  Queensland,  Toowoomba,  Queensland  4350,  Australia
f ORYGEN  Youth  Health  Research  Centre,  Centre  for  Youth  Mental  Health,  The  University  of  Melbourne,  Parkville,  Victoria  3052,
Australia
g The  Mental  Health  Research  Institute  of  Victoria,  Parkville,  Victoria  3052,  Australia
Available  online  30  January  2012
KEYWORDS
Antioxidant;
Diet;
Epidemiology;
Major  depressive
disorder;
Dietary  selenium;
Risk  factor;
Summary
Objectives  and  methods:  Alterations  in  redox  biology  are  established  in  depression;  however,
there are  no  prospective  epidemiological  data  on  redox-active  selenium  in  depression.  We  aimed
to determine  if  low  levels  of  dietary  selenium  are  associated  with  an  increased  risk  for  de  novo
major depressive  disorder  (MDD).  In  this  nested  case-control  study,  women  aged  20  years  or
more were  identiﬁed  from  a  randomly  selected  cohort  being  followed  prospectively  for  the
Geelong Osteoporosis  Study.  Cases  were  individuals  with  incident  MDD,  identiﬁed  using  the
Structured  Clinical  Interview  for  DSM-IV-TR  (SCID-I/NP);  controls  had  no  such  history.  DietaryWomen selenium intake  was  measured  using  a  food  frequency  questionnaire  at  baseline,  together  with
anthropometric  and  lifestyle  measures.
Results:  Eighteen  women  who  developed  de  novo  MDD  were  classiﬁed  as  cases;  there  were  298
controls. Low  dietary  selenium  intakes  increased  the  likelihood  of  developing  MDD;  OR  2.74
(95%CI 0.95—7.89).  After  adjusting  for  age  and  SES,  compared  with  a  high  selenium  intake,
a low  intake  (<8.9  g/MJ/day)  was  associated  with  an  approximate  trebling  of  the  likelihood
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for  developing  de  novo  MDD;  OR  2.95  (95%CI  1.00—8.72).  Smoking,  alcohol  consumption  and
physical activity  did  not  confound  the  association.
Conclusion:  These  data  suggest  that  lower  dietary  selenium  intakes  are  associated  with  an
increased risk  of  subsequent  de  novo  MDD.  We  propose  that  selenium’s  function  as  an  antiox-
idant, and  as  a  constituent  of  selenoproteins  that  are  important  in  redox  homeostasis,  warrants
further investigation  as  a  risk  factor  for  depression,  and  suggest  a  potentially  novel  modiﬁable
tion  and  management  of  depression.
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Areas  (SEIFA)  values  based  on  Census  Collection  District  data
from  the  Australian  Bureau  of  Statistics.  SEIFA  values  were
used  to  derive  an  Index  of  Occupation  and  Education  (IOE).factor in  the  primary  preven
© 2012  Elsevier  Ltd.  All  right
ntroduction
elenium  is  an  essential  micronutrient  in  humans,  although
t  is  toxic  in  large  doses.1 Selenium  is  incorporated  into
elenoproteins,  major  forms  of  which  are  the  glutathione
eroxidases  and  thioredoxin  reductases.  These  are  impor-
ant  antioxidants  that  reduce  hydrogen  peroxide  to  water,
nd  reduce  the  damaging  lipid  hydroperoxides  to  alcohol.1,2
elenium  inhibits  the  activation  of  NF-kappaB  by  modulat-
ng  the  expression  of  selenoprotein  genes  and  suppressing
-reactive  protein  production,  leading  to  attenuation  of
nﬂammation.3 Consequently,  selenium  may  play  a  role  in
nﬂammatory  disease,  and  might  modulate  clinical  out-
omes  in  infective  and  inﬂammatory  illnesses.
Depression  is  becoming  recognised  as  an  inﬂammatory
isorder,  accompanied  by  an  accumulation  of  highly  reactive
xygen  species  that  overwhelm  usual  defensive  physiolog-
cal  processes.4—11 Several  indicators  support  a  role  for
elenium  in  normal  brain  function.  During  times  of  sele-
ium  deﬁciency,  there  is  preferential  storage  of  selenium
n  the  brain.12 Selenium  has  signiﬁcant  modulatory  effects
n  dopamine13—15 and  dopamine  plays  a  role  in  the  patho-
hysiology  of  depression  and  other  psychiatric  illnesses.16,17
iminished  levels  of  selenium  in  the  brain  are  associ-
ted  with  cognitive  decline18 and  Alzheimer’s  disease.19
elenium  supplementation  has  been  linked  with  improve-
ents  in  mood20,21 and  protection  against  postpartum
epression.22
What  is  unclear  is  if  low  dietary  selenium  is  a  risk  factor
or  the  development  of  depression.  In  recognition  of  sele-
ium’s  biological  activity,  we  hypothesised  that  low  levels
f  dietary  selenium  would  be  associated  with  an  increased
isk  of  major  depressive  disorder  (MDD)  in  a  representative
opulation-based  sample  of  women.
ethods
tudy  subjects
his  study  focuses  on  women  enrolled  in  the  Geelong  Osteo-
orosis  Study  (GOS).  A  cohort  of  1494  women  was  selected  at
andom  from  the  Commonwealth  electoral  rolls  for  the  Bar-
on  Statistical  Division  in  south-eastern  Australia,  enrolled
n  the  period  1994—1997  with  77.1%  participation23 and
ollowed  prospectively  for  a  decade.  At  baseline,  sele-
ium  intakes  were  evaluated  for  575  randomly  selected
omen  aged  20—89  years;  19  individuals  who  had  anoma-ous  responses  on  dietary  questionnaires  were  excluded  (17
ere  incomplete  or  incorrectly  indicated  multiple  responses
o  frequency  of  food  consumption  and  two  were  outliers
ith  excessively  high  selenium  intakes).  Three  hundred  and
T
r
b
nerved.
ixteen  of  the  women  with  valid  dietary  questionnaires
lso  participated  in  a  psychiatric  interview  at  the  10-year
ollow-up,  fulﬁlling  eligibility  criteria  for  this  analysis.  Bar-
on  Health  Human  Research  Ethics  Committee  approved  the
tudy,  and  written  consent  was  obtained  from  all  partici-
ants.
ata
he  Structured  Clinical  Interview  for  DSM-IV-TR  Research
ersion,  Non-patient  edition  (SCID-I/NP)  was  used  to  identify
hose  with  a lifetime  history  of  MDD,  and  to  determine  age
f  onset.  Women  identiﬁed  as  having  experienced  de  novo
DD  in  the  years  following  baseline  were  cases;  those  with
o  such  history  were  controls.  Trained  personnel  conducted
sychiatric  interviews.
The  exposure  of  interest  was  dietary  selenium  intake.
etailed  semi-quantitative  food  frequency  questionnaires
ere  used  to  capture  responses  on  359  foods.24 The  ques-
ionnaire  records  both  the  frequency  (number  of  times
he  foods  were  consumed  daily,  weekly,  monthly  or  more
arely)  and  portion  size  (standard  or  speciﬁed  other)  of
oods  consumed  at  each  meal  time  (breakfast,  lunch,  dinner
nd  between  meal  snacks).  Additionally,  the  questionnaire
ought  details  about  food  preparation  and  cooking  methods
sed.  The  reproducibility  of  this  meal-based  questionnaire
ad  been  tested  previously.24 Selenium  intake  was  individ-
ally  estimated  from  available  food  data  according  to  the
ustralia  and  New  Zealand  Food  Authority  (ANZFA).  These
ata  were  available  for  raw  foods  including  most  fruits
nd  vegetables,  raw  ﬁsh  and  meats,  wheat  and  prepared
oods  such  as  bread,  biscuits,  breakfast  cereals  and  cooked
eats;  otherwise,  selenium  contents  were  estimated
rom  the  United  States  Department  of  Agriculture  (USDA)
atabank.25
Body  weight  and  height  were  measured  and  body
ass  index  (BMI)  calculated  as  weight/height2 (kg/m2).
ther  lifestyle  exposures  such  as  tobacco  smoking,  alco-
ol  consumption,  and  physical  activity  were  documented  by
elf-report  at  the  baseline  visit.  Smoking  was  described  as
ver/never;  alcohol  use  recognised  if  consumed  daily;  habit-
al  physical  activity  level  described  as  very  active  if  vigorous
xercise  was  performed  regularly;  and  socio-economic  sta-
us  (SES)  ascertained  using  the  Socio-Economic  Index  Forhis  was  categorised  into  quintiles  of  IOE  for  the  study
egion.  Quintiles  1  and  2  (low),  and  4  and  5  were  combined
ecause  of  small  numbers  to  create  three  categories  of  SES,
amely  low,  medium  and  high.
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Statistics
Daily  selenium  intakes  were  expressed  as  selenium  (g)
per  total  energy  intake  (MJ).  Selenium  intakes  (g/MJ/day)
were  categorised  as  high  and  low,  corresponding  to  groups
above  and  below  the  median.  Standard  descriptive  statistics
were  used  to  characterise  and  compare  cases  and  con-
trols.  Selenium  and  energy  intakes,  together  with  adjusted
selenium  intakes  (g/MJ/day)  were  skewed,  but  were  nor-
malised  by  natural  log  transformation.  Logistic  regression
models  were  used  to  determine  the  association  between
exposure  to  high  or  low  selenium  intakes  and  the  likelihood
of  developing  MDD  during  the  period  of  follow-up.  Smoking,
alcohol  use,  physical  activity,  age  and  SES  were  investigated
as  confounders  and  effect  modiﬁers.  Statistical  analyses
were  performed  using  Stata  (release  9.0,  StataCorp,  College
Station,  TX)  and  Minitab  (version  15;  Minitab,  State  College,
PA).
Results
The  median  selenium  intake  was  71.2  g/day  (interquar-
tile  range,  IQR,  55.9—87.0).  One  hundred  and  one  women
(32.0%)  had  intakes  below  the  Australian  recommended
daily  intake  of  60  g/day;  no  toxic  levels  were  found.
There  was  a  strong  correlation  between  selenium  intake
and  energy  intake  (both  log  transformed,  r  =  0.7,  p  <  0.001).
Median  selenium  intake  corrected  for  energy  intake  was
8.9  g/MJ/day  (IQR  7.7—10.5).  Subject  characteristics  are
shown  for  cases  and  controls  in  Table  1.  No  differences
in  socio-demographic  or  lifestyle  factors  were  detected
between  cases  and  controls.
Eighteen  women  developed  de  novo  MDD  over  the  study
period  and  were  classiﬁed  as  cases;  there  were  298  con-
trols.  A  low  selenium  intake  was  associated  with  greater
odds  for  de  novo  MDD;  OR  2.74  (95%CI  0.95—7.89),  p  =  0.06.
After  adjusting  for  age  and  SES,  the  OR  was  2.95  (95%CI
1.00—8.72),  p  =  0.05.  These  data  provide  moderate  evidence
to  reject  the  null  hypothesis  of  no  difference  in  the  likeli-
hood  of  developing  MDD  between  the  groups  with  high  and
low  selenium  intakes.  Further  adjustment  for  smoking,  alco-
hol  use  and  physical  activity  did  not  impact  on  the  point
estimate.
Discussion
Our  results  support  the  hypothesis  that  lower  dietary  sele-
nium  intakes  increase  the  risk  of  subsequent  de  novo  MDD.
Selenium-rich  foods  include  brazil  nuts,  kidneys,  liver,  ﬁsh
and  eggs;  however,  wheat  products,  ﬁsh,  vegetables,  beef
and  fruit  provide  most  of  the  daily  selenium  intake  among
Australian  women  living  in  the  study  region.25 These  ﬁndings
are  in  accordance  with  previously  published  data  show-
ing  that  diets  rich  in  wholefoods  are  associated  with  a
reduced  likelihood  for  depression  and  anxiety.26,27 Although
the  median  selenium  intake  of  women  in  this  study  was  in
accordance  with  the  National  Health  and  Medical  Research
Council  (Australia)  guidelines,  it  is  noteworthy  that  one-
third  of  the  women  consumed  less  than  the  recommended
daily  intake.  The  strong  correlation  between  daily  total
i
n
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nergy  and  selenium  intakes  suggests  that  energy-restricted
iets  may  increase  the  risk  of  selenium  insufﬁciency
The  characteristics  of  the  study  require  noting  in  inter-
reting  the  results.  As  we  were  limited  by  small  numbers,
elenium  intakes  were  dichotomised  rather  than  being  cat-
gorised  into  smaller  groups,  such  as  tertiles  or  quartiles;
urther  research  is  required  to  investigate  dose  and/or
hreshold  effects.  The  potential  for  differential  recall  bias
n  the  food  frequency  questionnaire  responses  has  been
inimised  by  nesting  the  study  within  a larger  prospec-
ive  cohort  study  and  by  recording  dietary  histories  before
he  onset  of  MDD.  As  depression  can  impact  on  self-care
nd  dietary  patterns,  it  was  important  to  exclude  women
ith  prior  depression;  however,  the  possibility  of  reverse
ausality  cannot  be  deﬁnitively  excluded.  Psychiatric  inter-
iews  were  administered  by  trained  personnel  who  were
linded  to  baseline  dietary  histories.  Also,  changes  in  dietary
ntakes  of  selenium  over  the  period  of  follow-up  have  not
een  identiﬁed;  misclassiﬁcation  of  selenium  intakes  would
ikely  attenuate  the  reported  association  between  selenium
ntake  and  likelihood  of  MDD.  Selenium  is  found  in  a  variety
f  foods  and,  as  the  selenium  content  varies  according  to
he  selenium  content  of  soil,28 we  cannot  assume  that  the
elenium  intakes  have  been  accurately  calculated  for  this
egion.  Variation  in  selenium  content  is  particularly  evident
mong  plant  food  sources,  where  much  of  the  selenium  is  in
he  form  of  selenomethionine,  selenocysteine  or  selenocys-
eine  metabolites,  but  there  is  less  variation  in  the  selenium
ontent  of  muscle  meats  and  seafood.  Findings  from  this
tudy  may  not  be  generaliseable  to  populations  drawn  from
ther  regions  and,  furthermore,  may  not  be  applicable  to
en.
In  a  double-blind  US  study  involving  11  men  conﬁned
o  a  metabolic  unit  for  120  days,  low  pre-baseline  dietary
elenium  was  associated  with  poor  mood.29 Subsequent
ntervention  with  a  high  selenium  diet  of  356  g/day  for
9  days,  resulted  in  no  improvement  in  mood;  however,  it
s  possible  that  the  psychological  effects  of  being  conﬁned
ay  have  negated  any  beneﬁcial  effects  of  the  selenium
upplementation.  In  another  US  study  of  30  men  allocated
o  either  a  low  or  high  selenium  diet  (32.6  vs.  226.5  g/day),
ood  deteriorated  with  the  low  diet  and  improved  with  the
igh  diet.20 In  a  double  blind  cross-over  trial  of  50  British
ndividuals,  selenium  supplementation  with  100  g/day  for
ve  weeks  evoked  improvement  in  depression,  with  a
reater  effect  among  those  with  poorer  dietary  selenium
ntakes.21 In  contrast,  a  larger  randomised-controlled  trial
mong  501  elderly  volunteers  in  the  UK  showed  no  such
ffect.30
The  glutathione  antioxidant  system  is  implicated  in  the
athophysiology  of  mood  disorders.7 Selenium  is  a  criti-
al  cofactor  for  the  enzyme,  glutathione  peroxidase,31 as
ell  as  the  thioredoxin  antioxidant  system.  Further  sup-
ort  for  a  role  of  the  glutathione  system  in  psychopathology
omes  from  clinical  trials  involving  treatment  with  N-acetyl
ysteine  (NAC),  a  precursor  of  cysteine  and  glutathione.32
ecent  double-blind  randomised  placebo  controlled  trials
f  NAC  have  shown  improvements  in  depressive  symptoms
n  bipolar  disorder33,34 and  schizophrenia.32,35
In  addition  to  selenium’s  putative  protective  role  against
eurodegeneration,18,19 selenium  has  been  implicated  in
mmunoprotection 36 and  cancer  prevention.37 Because
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Table  1  Characteristics  are  shown  for  cases  (with  MDD)  and  controls.  Data  are  shown  as  mean  (±SD),  median  (interquartile
range, IQR)  or  number  (%).
Cases  (n  =  18) Controls  (n  =  298)  P-Value
Age  (year),  median  (IQR)  49.5  (37.0—63.5)  48.4  (35.3—61.4)  0.6
Energy intake  (MJ/day),  median  (IQR)  7.93  (6.30—9.42)  7.95  (6.32—9.37)  0.9
Weight (kg),  mean  (±SD) 70.6  (±10.6)  68.1  (±12.5)  0.4
Height (cm),  mean  (±SD) 163.1  (±7.6) 161.7  (±6.1) 0.3
Body mass  index  (kg/m2),  mean  (±SD)  26.6  (±4.5) 26.1  (±4.8) 0.6
Smokers,  n  (%) 6  (33.3%) 94  (31.5%) 0.9
Daily alcohol  use,  n  (%)  0  (0.0%)  25  (8.4%)  0.4
Physically active,  n  (%)  3  (16.7%)  37  (12.4%)  0.5
Socio-economic  status,  n  (%)  0.2
Low 9  (50.0%)  88  (29.5%)
Medium 4  (22.2%)  69  (23.2%)
High 5  (27.8%)  141  (47.3%)
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xidative  stress,  it  is  hypothesised  that  selenium’s  biological
ctivity  as  an  antioxidant  could  underpin  these  ﬁndings  as
ell.
In  conclusion,  our  data  suggest  that  a  lower  dietary
elenium  intake  is  associated  with  an  increased  risk  of  de
ovo  MDD,  supporting  a  role  for  selenium  in  mood.  Further
esearch  focused  on  the  implications  of  low  selenium  intakes
n  other  populations  is  warranted  and  may  provide  a  ratio-
ale  for  future  randomised  controlled  clinical  trials  to  assess
otential  beneﬁts  of  selenium  (either  alone  or  in  combina-
ion  with  other  key  nutrients)  as  a  novel  modiﬁable  factor
n  the  primary  prevention  and  management  of  depression.
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